Growth momentum Skye shows ongoing clinical development activity with multiple Q2 2026 milestones including Cohort 2 expansion and a focus on Phase 2b readiness, signaling continued need for strategic partnerships, advisory support, and channel-aligned equipment or services to support regulatory and trial operations.

Clinical collaboration Active engagement in external development advisors and study collaborations (ENHANZE compatibility, dose-selection rationale) indicates opportunities to offer consulting, CRO support, or technology platforms that streamline trial design, data analytics, and regulatory submissions.

Safety focused A CRC driven safety review process for cohort expansion highlights a buyer preference for rigorous safety and monitoring solutions, which could translate into offerings around data monitoring, safety analytics, and compliant trial governance tools.

BIotech investor signals Public updates and quarterly results with emphasis on advancing CBeyond into Phase 2b suggest a potential interest in narrative-aligned investor relations services, strategic communications, or investor collateral that clearly conveys risk-adjusted development timelines.

Scaling capabilities Plans for higher-volume subcutaneous administration studies and GLP-1 combination programs point to demand for temperature-controlled logistics, supply chain optimization, and scalable manufacturing or formulation services to support larger trial cohorts.